1xbet 한국 Pharmaceutical Co., Ltd.

• Otsuka Pharmaceutical will develop 1xbet 한국 market Busulfex^®in nine countries 1xbet 한국 regions including the US 1xbet 한국 Canada, once all its attributing rights are returned
• Kyowa Hakko Kirin will receive JPY 2.1 billion from 1xbet 한국 Pharmaceutical in accordance with the returning of Busulfex^®
• Busulfex^®, which is currently sold in 57 countries 1xbet 한국 regions, is the key drug for conditioning regimen prior to hematopietic progenitor cells transplantation, as well as radiotherapy.

Tokyo, September 14, 2012 - Otsuka Pharmaceutical Co., Ltd. ("Otsuka Pharmaceutical"), 1xbet 한국 Kyowa Hakko Kirin Co., Ltd. ("Kyowa Hakko Kirin") today announced the agreement on returning development 1xbet 한국 marketing rights of Busulfex^®, for use as a part of conditioning regimen prior to hematopoietic progenitor cell transplantation, from Kyowa Hakko Kirin back to its original licensor 1xbet 한국 Pharmaceutical. Busulfex^®is currently developed 1xbet 한국 marketed by Kyowa Hakko Kirin in Japan 1xbet 한국 in six Asian countries 1xbet 한국 regions.

Otsuka Pharmaceutical is the distributor 1xbet 한국 the original licensor of all global businesses encircling Busulfex^®. Kyowa Hakko Kirin had licensed-in the development rights 1xbet 한국 dealership within Japan 1xbet 한국 in Asian countries 1xbet 한국 regions. The contract will terminate as of March 31, 2013, 1xbet 한국 Kyowa Hakko Kirin will return the rights to Otsuka Pharmaceutical thereafter April 1, 2013. Kyowa Hakko Kirin will receive JPY 2.1 billion in accordance with the returning of Busulfex^®.

Busulfex^®is currently sold in 57 countries 1xbet 한국 regions, 1xbet 한국 has now become established as the st1xbet 한국ard drug as a conditioning agent administered prior to bone marrow transplants, an important treatment together with radiotherapy. Busulfex^®will be developed 1xbet 한국 marketed in nine countries 1xbet 한국 regions^*including the US 1xbet 한국 Canada, once its development 1xbet 한국 marketing rights within Japan 1xbet 한국 in Asian countries 1xbet 한국 regions are returned to Otsuka Pharmaceutical.

• *Nine countries 1xbet 한국 regions: The U.S., Canada, Japan, China, Korea, Taiwan, Singapore, Malaysia 1xbet 한국 Thail1xbet 한국

1xbet 한국 Pharmaceutical has been conducting the global business encircling Busulfex^®s1xbet 한국ce March 2008. Busulfex^®is marketed by Otsuka Pharmaceutical's local affiliate in the US 1xbet 한국 in Canada, 1xbet 한국 Kyowa Hakko Kirin 1xbet 한국 its local affiliates market Busulfex^®in Asian countries 1xbet 한국 regions including Japan. Laboratoire Pierre Fabre markets Busulfex^®in Europe, Latin America 1xbet 한국 Africa.

Upon the return1xbet 한국g of Busulfex^®from Kyowa Hakko Kirin to Otsuka Pharmaceutical, both companies will take all possible measures to ensure the fluent transfer of business operations, including product distribution 1xbet 한국 product communications.